Drug Profile
Tenofovir exalidex - Hepion Pharmaceuticals
Alternative Names: CMX-157; HDP-Tenofovir; Hexadecyloxypropyl-tenofovir; lipid conjugate TFV(tenofovir); Lipid conjugate YTFV; TXLLatest Information Update: 28 Oct 2020
Price :
$50
*
At a glance
- Originator Chimerix
- Developer Chimerix; Hepion Pharmaceuticals
- Class Antiretrovirals; Phosphonic acids; Purines; Small molecules
- Mechanism of Action Nucleotide reverse transcriptase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Hepatitis B
Highest Development Phases
- Phase II Hepatitis B
- Suspended HIV infections
Most Recent Events
- 28 Oct 2020 No recent reports of development identified for phase-I development in Hepatitis-B(In volunteers) in United Kingdom (PO)
- 28 Oct 2020 No recent reports of development identified for phase-I development in Hepatitis-B(In volunteers) in USA (PO)
- 22 Jul 2019 ContraVir Pharmaceuticals is now called Hepion Pharmaceuticals